ONCAlert | Upfront Therapy for mRCC

Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast Cancer

Peter Kaufman, MD
Published Online: 8:08 PM, Tue June 6, 2017

Peter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.